Welcome to LookChem.com Sign In|Join Free
  • or
a-chloro-dc-[2-(2'-pyridyl)phenyl-N',C]-b-(triphenylphosphine)platinum is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

872729-59-4

Post Buying Request

872729-59-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

872729-59-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 872729-59-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,7,2 and 9 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 872729-59:
(8*8)+(7*7)+(6*2)+(5*7)+(4*2)+(3*9)+(2*5)+(1*9)=214
214 % 10 = 4
So 872729-59-4 is a valid CAS Registry Number.

872729-59-4Downstream Products

872729-59-4Relevant academic research and scientific papers

Cyclometalated platinum(II) complexes containing monodentate phosphines: Antiproliferative study

Samouei, Hamidreza,Rashidi, Mehdi,Heinemann, Frank W.

, p. 1207 - 1216 (2014)

Reaction of cyclometalated platinum(II) precursor [Pt(C∧N)Cl(dmso)], 1, C∧N = N(1), C(2′)-chelated deprotonated 2-phenylpyridine and dmso = dimethylsulfoxide, with 1 equivalent of triphenyl phosphine, PPh3, or 1,3,5-triaza-7-phosphaadamantane, PTA, gave the complex [Pt(C∧N)Cl(PPh 3)], 2, or [Pt(C∧N)Cl(PTA)], 3, respectively. On the basis of careful multinuclear NMR spectroscopy, supported by a number of 2D NMR experiments, structures of the complexes 2 and 3 in solution were determined to be neutral four coordinate. The X-ray crystallography indicated that the solid-state structure of complex 3 comprised a common square-planar geometry around platinum(II). Cytotoxicity of the complexes 2 and 3 was studied in three human cancer cell lines derived from ovarian carcinoma (CH1), lung carcinoma (A549), and colon carcinoma (SW480).

Improvement of the photophysical performance of platinum-cyclometalated complexes in halogen-bonded adducts

Sivchik, Vasily,Sarker, Rajib Kumar,Liu, Zong-Ying,Chung, Kun-You,Grachova, Elena V.,Karttunen, Antti J.,Chou, Pi-Tai,Koshevoy, Igor O.

, p. 11475 - 11484 (2018)

Three groups of luminescent platinum complexes [Pt(C^N)(L)(Y)] [C^N = benzothienyl-pyridine (1), bezofuryl-pyridine (2), phenyl-pyridine (3); L/Y = DMSO/Cl (a), PPh3/Cl (b), PPh3/CN (c)] have been probed as halogen-bond (XB) ac-ceptors towards iodofluorobenzenes (IC6F5 and I2C6F4). Compounds 1a and 2 a (L/Y =DMSO/Cl) afford the adducts 1 a···I2C6F4 and 2 a···I2C6F4, which feature I···Sbtpy/I···πbtpy and I···ODMSO/I···Cl short contacts, respectively. The phosphane-cy-anide derivatives 1 c and 2 c (L/Y = PPh3/CN) co-crystallise with both IC6F5 and I2C6F4. None of the phpy-based species 3 a–3 c participated in XB interactions. Although the native complexes are rather poor luminophores in the solid state (Φem = 0.023–0.089), the adducts exhibit an up to 10-fold increase of the intensity with a minor alteration of the emission energy. The observed gain in the quantum efficiency is mainly attributed to the joint influence of non-covalent interactions (halogen/hydrogen bonding, π–π stacking), which govern the crystal-packing mode and diminish the radiation-less pathways for the T1→S0 transition by providing a rigid environment around the chromophore.

Coordination to Imidazole Ring Switches on Phosphorescence of Platinum Cyclometalated Complexes: The Route to Selective Labeling of Peptides and Proteins via Histidine Residues

Solomatina, Anastasia I.,Chelushkin, Pavel S.,Krupenya, Dmitrii V.,Podkorytov, Ivan S.,Artamonova, Tatiana O.,Sizov, Vladimir V.,Melnikov, Alexei S.,Gurzhiy, Vladislav V.,Koshel, Elena I.,Shcheslavskiy, Vladislav I.,Tunik, Sergey P.

, p. 426 - 437 (2017)

In this study, we have shown that substitution of chloride ligand for imidazole (Im) ring in the cyclometalated platinum complex Pt(phpy)(PPh3)Cl (1; phpy, 2-phenylpyridine; PPh3, triphenylphosphine), which is nonemissive in solution, switches on phosphorescence of the resulting compound. Crystallographic and nuclear magnetic resonance (NMR) spectroscopic studies of the substitution product showed that the luminescence ignition is a result of Im coordination to give the [Pt(phpy)(Im)(PPh3)]Cl complex. The other imidazole-containing biomolecules, such as histidine and histidine-containing peptides and proteins, also trigger luminescence of the substitution products. The complex 1 proved to be highly selective toward the imidazole ring coordination that allows site-specific labeling of peptides and proteins with 1 using the route, which is orthogonal to the common bioconjugation schemes via lysine, aspartic and glutamic acids, or cysteine and does not require any preliminary modification of a biomolecule. The utility of this approach was demonstrated on (i) site-specific modification of the ubiquitin, a small protein that contains only one His residue in its sequence, and (ii) preparation of nonaggregated HSA-based Pt phosphorescent probe. The latter particles easily internalize into the live HeLa cells and display a high potential for live-cell phosphorescence lifetime imaging (PLIM) as well as for advanced correlation PLIM and FLIM experiments.

In vitro and in vivo studies of neutral cyclometallated complexes against murine leukaemias

Edwards, Gavin L.,Black, David St.C.,Deacon, Glen B.,Wakelin, Laurence P.G.

, p. 980 - 989 (2007/10/03)

Cyclometallated μ-halogeno dimers derived from nitrogen donor ligands (1-phenylpyrazoles, 2-phenylpyridine, and 1-(2′-pyridyl)indole) were treated with unidentate nitrogen and phosphorus donor ligands to give a series of neutral monomeric palladium(II) and platinum(II) complexes. An initial prescreen of the complexes against the mouse lymphoid leukaemia cell line Ll210 indicated that the complexes exhibited growth inhibitory activity over a relatively wide concentration range. Two factors that gave rise to increased activity were steric hindrance about the metal centre resulting from hindered ligands such as 2,6-dimethylpyridine, or the presence of a phosphorus donor ligand. Little correlation between palladium and platinum complexes was noted. Four complexes were selected for further in vivo study and, while none of the palladium complexes showed more than marginal activity against P388 leukaemia at doses below toxic levels, one platinum complex with a hindered metal centre did display significant antitumour activity against this model.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 872729-59-4